Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy

J Med Virol. 2002 May;67(1):88-91. doi: 10.1002/jmv.2195.

Abstract

Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir. Foscarnet-resistant isolates with DNA polymerase mutations in regions II, VI, and between I and VII were also associated with an important decrease in susceptibility to adefovir (mean IC50 increase: 4.6-fold compared to pre-foscarnet or wild-type isolates) suggesting that adefovir-resistant HSV could be selected in vivo by foscarnet therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / virology*
  • Adenine / analogs & derivatives*
  • Adenine / pharmacology*
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use
  • Foscarnet / therapeutic use
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • Herpes Genitalis / virology*
  • Herpes Simplex / virology*
  • Herpesvirus 1, Human / drug effects
  • Herpesvirus 1, Human / genetics
  • Herpesvirus 1, Human / isolation & purification
  • Herpesvirus 2, Human / drug effects
  • Herpesvirus 2, Human / genetics
  • Herpesvirus 2, Human / isolation & purification
  • Humans
  • Organophosphonates*
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Reverse Transcriptase Inhibitors / therapeutic use

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Reverse Transcriptase Inhibitors
  • Foscarnet
  • adefovir
  • Adenine